

Bacteriocin-rich extract from engineered lactic acid bacteria as an antibiotic alternative in ruminants and aquaculture (BAC4RumA)

Project No: 11037

Ismail A. Odetokun (DVM, Ph.D.)

Associate Professor

Department of Veterinary Public Health & Preventive Medicine

University of Ilorin, Nigeria

odetokun.ia@unilorin.edu.ng; +2348030886018





The AMR Challenge in Africa

- **AMR threatens food security, livelihoods, and public health.**
- **Over-reliance on antibiotics in livestock and aquaculture.**
- **Limited, non-accessible and non-affordable diagnostics, lack of implementation of regulations, poor awareness.**




Mastitis in Ruminants (Nigeria)

- **30% prevalence across Africa; up to 85% in Nigerian herds (Adamu et al. 2020)**
- **Socioeconomic losses from decreased milk yield, treatment cost and food safety and security.**
- **70% of farms use antibiotics without a prescription (Alhaji et al., 2019)**

Tilapia farming in Nigeria

- **Nigeria is the largest aquaculture producer in SSA (300,000 tons/yr)**
- **Changing production system has led to overreliance on antibiotics to control outbreaks and reduce economic loss**
- **Antibiotic misuse contaminates water systems and the environment.**

Antibiotic use for livestock and aquaculture in Nigeria



Antibiotic consumption globally

2010: 63,000 tons


2030: 106,000 tons

Nigeria (163%)

(Laxminarayan et al., 2015; Van Boeckel et al. 2015)

Mulchandani et al., 2023

Our project





IDRC · CRDI

International Development Research Centre
Centre de recherches pour le développement international




Canada



Department of Health & Social Care




Farm characteristics and treatment decisions among farmers




Tilapia farm survey: Key findings

- **More than 30% of farmers reported having a disease problem in the last production cycle.**
- **Disease affects all farmers indiscriminately, regardless of demographics.**
- **Farmers had a wide range of years of experience in aquaculture.**
- **Tilapia farmers still use antibiotics in fish feed.**




Tilapia farm survey: Key findings

- **There is limited knowledge of AMR amongst tilapia farmers.**
- **Few farmers highlighted the harmful effects of antibiotic misuse, while others listed the antibiotics commonly used in tilapia farming.**
- **More farmers receive training from government organisations than from other sources, except for feed management, where more farmers receive training from feed companies.**
- **Training does not affect mortality rates or disease outbreaks, regardless of who delivers the training.**




Ruminant farm survey: Key findings

- **>30%** of farmers reported having mastitis in their cattle in the last 12 month.
- The average number of cases was **2** per farm over the last 12 month.
- **>25%** of cases were clinical mastitis.
- **>46%** of farmers started treatment of mastitis without consulting vets.
- **>44%** of farmers are using ABs without prescription.
- **>56%** cull animals due to persistent mastitis.




Ruminant survey

How do you know when there is a problem in your farm?




Ruminant survey

What are the main challenges and diseases that affect your herd?




Ruminant survey


What do farmers around you do when they have these diseases?



What do you do when you suspect a case of mastitis?





What do you use to prevent mastitis?



What alternatives to antibiotics do you use?

- Herbal remedies
- Salt
- Biomedical Products
- Biosecurity
- Heat Treatment
- I don't know
- Won't tell you




Engineering bacteriocins



Engineering the bacteriocins

Tetrameric concatenation of bacteriocins



x4 monomeric bacteriocins interconnected by **flexible linkers** to allow for combined activity

Roca-Pinilla, R., López-Cano, A., Saubi, C. *et al.* A new generation of recombinant polypeptides combines multiple protein domains for effective antimicrobial activity. *Microb Cell Fact* **19**, 122 (2020). <https://doi.org/10.1186/s12934-020-01380-7>

Recombinant production hosts



Lactococcus lactis NZ9000




Escherichia coli BL21

Antimicrobial activity assessment *in vitro*


Bactericidal activity

BacTiter Glo assay, cell concentration starting at 10^7 cfu/mL for MSSA and 10^8 cfu/mL for both *S. agalactiae* and MRSA


MSSA



S. agalactiae CECT 183



MRSA



E. coli BL21-produced and intracellularly purified bacteriocins

Control: positive control for growth - untreated cells

*Data statistically validated with Tukey-HSD

Antimicrobial activity assessment *in vitro*

Bacteriostatic activity

MIC determination, cell concentration starting at $5 \cdot 10^5$ cfu/mL

Engineered bacteriocin	Challenged pathogen, MIC in μ M		
	MSSA	MRSA	<i>S. agalactiae</i> CECT 183
<i>EntPx4</i>	2.50	2.5	1.25
<i>Aur53x4</i>	1.25	0.6	1.25
<i>SakPx4</i>	2.50	2.5	2.50
<i>PedAx4</i>	2.50	2.5	2.50

E. coli BL21-produced and intracellularly purified bacteriocins

*MSSA = Methicillin-sensitive *S. aureus*


*MRSA = Methicillin-resistant *S. aureus*

EntPx4 and Aur53x4 show to be more effective in inhibiting the growth of these pathogens, showing lower MICs than SakPx4 and PedAx4 in every case

Bioprocess upscaling for *in vivo* experiments

For the *E. coli* BL21 intracellularly-produced proteins:

- Integrates easily with local dairy and fish-feed systems.
- No refrigeration
- Residue-free.
- Low-cost production
- Affordable to smallholders



Bacteriocin	Production rate : mg/L culture	
	Small scale - Flasks	Small scale - Bioreactor
EntPx4	0.19	4.5
Aur53x4	0.50	10

→ **x20 increase in
bacteriocin bioprocess
productivity**

Policy and regulatory pathway

- **Simplified approval frameworks for biologically derived antimicrobials. E.g. NAFDAC.**
- **Public–private partnerships for scale-up.**
- **Policy endorsement will enable commercialization and uptake.**
- **We hope that WOAH's manuals would include bacteriocins and other non-vaccine alternatives.**



Team members



Acknowledgements



IDRC • CRDI

International Development Research Centre
Centre de recherches pour le développement international

Canada



GAMRIF
Global AMR Innovation Fund



UKaid
from the British people

BAC4RumA

IRTA

R

Instituto
de Investigación y Tecnología
Agroalimentarias



**ROYAL
HOLLOWAY
UNIVERSITY
OF LONDON**

**Thank you
for
listening!**

